
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is well-positioned in the regenerative medicine market with a diverse portfolio of products and a strong management team. While they may face short-term challenges due to changes in CMS reimbursement rates, their upcoming product ReNu has the potential for growth and the company is expected to benefit from CMS's revised LCDs. With a current undervaluation and potential for market consolidation, Organogenesis could be a strong investment opportunity.
Bears say
Organogenesis Holdings is facing significant short term margin and profitability impacts, with expected negative EBITDA in 2026 due to lower revenue. With a pureplay exposure to the reimbursement changes in the regenerative medicine space and a lower revenue growth profile compared to peers, a discount is warranted for the stock, which we have valued at approximately 1.4x EV/Sales for 2027E revenue and 1.2x for 2028E revenue. Additionally, there are significant risks associated with reimbursement changes, clinical product development, and market consolidation.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares